NEPHHealthcare · Medical Instruments & SuppliesThe 3 Wall Street analysts covering Nephros, Inc. hold a median 12-month price target of $6 — +84.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Nephros, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (93): The business earns solid, repeatable profits on what it owns.
Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NEPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +84.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Aug 2025 | Maxim Group | Maintains | Buy | $4.50 → $6.00 |
| 12 Nov 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 15 May 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 8 Mar 2024 | Benchmark | Upgrade | Speculative Buy | — |
| 26 Jan 2021 | B. Riley FBR | Initiates | Buy | $13 |
| 26 Jan 2021 | B. Riley Securities | Initiates | Buy | — |
| 25 Nov 2020 | Benchmark | Initiates | Speculative Buy | — |
| 25 Nov 2020 | Maxim Group | Initiates | Buy | — |
| 24 Oct 2019 | Benchmark | Initiates | Speculative Buy | — |
| 4 Oct 2019 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NEPH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Nephros, Inc. returned −37.5% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 55% of US stocks
Cheaper than 31% of US stocks
Cheaper than 17% of US stocks
Higher than 81% of US stocks
Higher than 94% of US stocks
Higher than 80% of US stocks
Higher than 79% of US stocks
Higher than 66% of US stocks
Higher than 76% of US stocks
Higher than 86% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nephros, Inc. has a market value of $35.2M and an enterprise value of $31.4M.
Revenue in the twelve months to 30 June 2026: $20.7M. The latest quarter grew 36.2% year on year.
Net income over the same four quarters: $1.7M, a 8.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$661K.
Trailing P/E: 21.5×; forward P/E: 15.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nephros, Inc. employs 36 people — $576K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nephros, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nephros announced that it has scheduled a conference call to discuss its third-quarter 2026 financial results. The excerpt identifies the announcement date as October 29, 2026.
Why it matters — The call schedule provides NEPH watchers with information about when the company will discuss its quarterly results.
Nephros announced it will file its third-quarter 2026 financial results after market close on November 5, 2026, and host a conference call that day at 4:30 p.m. ET.
Why it matters — NEPH watchers can note when the company will release its quarterly results and discuss them on a call.
Nephros, Inc. held a Q2 2026 earnings call, and a transcript of the call was published by Seeking Alpha. The item announces the availability of the full earnings call transcript for the quarter.
Why it matters — A NEPH watcher would care because the earnings call transcript provides management's discussion of the company's Q2 2026 results and outlook.
Nephros, Inc. announced strong financial results for the quarter ended June 30, 2026, with record second-quarter net revenue growth of 36% to $6 million. Core programmatic revenue grew 27% year over year.
Why it matters — NEPH watchers would note the company's record quarterly revenue and continued year-over-year growth in its core programmatic business.
Nephros, Inc. announced it will file its second quarter 2026 financial results on Thursday, August 06, 2026 after market close and host a conference call that same day at 4:30pm ET. The company noted its focus on water filtration solutions for medical and commercial markets.
Why it matters — A NEPH watcher would care because the scheduled earnings release and conference call provide the next scheduled opportunity to review the company's second quarter financial performance.
The 3 Wall Street analysts covering Nephros, Inc. have a median 12-month price target of $6, with estimates ranging from $4.75 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Nephros, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nephros, Inc. 84 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Nephros, Inc. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +84.6% from the last close, and Ticker Nerd's factor model ranks Nephros, Inc. 84 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nephros, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.75 to $8 over the next 12 months.
Nephros, Inc. returned -37.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Nephros Inc. is a commercial-stage water technology company focused on filtration solutions for medical and commercial markets.
The most recent item we track (MCAP MediaWire, 29 Oct 2026): "�Nephros Schedules Third Quarter 2026 Financial Results Conference Call". Nephros announced that it has scheduled a conference call to discuss its third-quarter 2026 financial results. The excerpt identifies the announcement date as October 29, 2026.
Nephros Inc. is a commercial-stage water technology company focused on filtration solutions for medical and commercial markets. Nephros develops and sells ultrafiltration products used in hospitals, dialysis centers, and other healthcare settings to help remove biological contaminants and support infection control. Its product portfolio also includes commercial water filters designed to improve water taste and odor while reducing biofilm, bacteria, cysts, particulates, and scale in downstream equipment. The company serves customers across healthcare, food service, hospitality, convenience retail, and other water-sensitive environments. Nephros also offers pathogen detection systems and water-quality education as part of its broader approach to water safety. Based in South Orange, New Jersey, Nephros operates with a strong emphasis on water purification, contamination reduction, and practical water-management applications in specialized markets.
CEO Mr. Robert Banks · 36 employees · United States · https://www.nephros.com
